FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution
This article was originally published in The Tan Sheet
Executive Summary
Culture change, not congressional action, is needed to change clinical trials system and move toward faster drug development, FDA’s drug center director tells the Energy & Commerce Committee.
You may also be interested in...
Major Pharmas To Collaborate In Non-Profit Initiative To Resolve Clinical Development Hurdles
Called TransCelerate BioPharma, the initiative funded by 10 big drug firms will work to develop uniform clinical data standards and certification for trial sites and investigators, with deliverables expected by mid-2013.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.